The White House and US Food and Drug Administration are ramping up research on an old anti-malarial drug, currently in short supply and carrying a potentially concerning safety profile, as a possible treatment for coronavirus.
White House Hypes Chloroquine, A Drug Currently In Shortage, As Coronavirus Treatment Hope
Efficacy trials are under way and one supplier already has said it would restart production to meet the anticipated demand.
More from Manufacturing
• By
While the pharma industry appears to be exempt from US tariffs imposed by President Trump, a member of the UK House of Lords says the details are unknown and warned that uncertainty “leads to less investment” in business as a whole.
• By
Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.